Status:
COMPLETED
Safety and Efficacy of BFH772 in Psoriasis Patients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Psoriasis
Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.
Eligibility Criteria
Inclusion
- Stable mild to moderate plaque psoriasis (BSA involvement \< 10% or PASI \< 10
- Category "mild to moderate" on PGA as according to the EMEA (CHMP 2004) (Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis), with or without arthritis
- Diagnosed or history of psoriasis for at least 6 months prior to screening
Exclusion
- Nonplaque forms of psoriasis
- Drug-induced psoriasis
- Current use of beta blockers
- Congestive heart failure (NYHA \>III), QT interval \>450msec or poorly controlled diabetes mellitus
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00987870
Start Date
September 1 2009
Last Update
March 28 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigator Site
Berlin, Germany